The aim of this study was to evaluate the relationships between the molecular properties, ocular pharmacokinetics, and the pharmacology of the anti-VEGF agents aflibercept, brolucizumab, and ranibizumab, and to apply a framework of mathematical models to characterize their efficacy in a preclinical animal model of retinopathy. Here, VEGFA is linked to retinal disorder.